VYVGART

This brand name is authorized in United States. It is also authorized in Austria, Croatia, France, Israel, Italy, Japan, Lithuania, Romania.

Active ingredients

The drug VYVGART contains one active pharmaceutical ingredient (API):

1	Efgartigimod alfa UNII 961YV2O515 - EFGARTIGIMOD ALFA
	Efgartigimod alfa is a human IgG1 antibody fragment engineered for increased affinity to the neonatal Fc Receptor (FcRn). Efgartigimod alfa binds to FcRn, resulting in a reduction in the levels of circulating IgG including pathogenic IgG autoantibodies. Efgartigimod alfa does not affect the levels of other immunoglobulins (IgA, IgD, IgE or IgM), or those of albumin.
	Read more about Efgartigimod alfa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VYVGART Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AA58		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA58

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	66371262, 69419901
IL	מִשְׂרַד הַבְּרִיאוּת	9264
IT	Agenzia del Farmaco	050235011, 050235023
JP	医薬品医療機器総合機構	6399430A1029
LT	Valstybinė vaistų kontrolės tarnyba	1095371
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69156001
US	FDA, National Drug Code	73475-3041